[Therapy with recombinant growth hormone].
Therapy with recombinant growth hormone is currently approved for the indications growth hormone deficiency,Turner syndrome, chronic renal failure, small for gestational age (SGA) and Prader-Willi syndrome. Positive experience from on-going clinical studies (e.g. on obesity, type 2 diabetes, Crohn's disease) support an extended range of applications for recombinant growth hormone. However, growth hormone therapy is very expensive. On the other hand, biosimilars are already available that are significantly lower in price. During the coming years, research must show whether the efficacy and safety of biosimilars (including possible new indications) are equal to that of the established preparations.
Sektion Pädiatrische Endokrinologie, Universitätsklinik für Kinder- und Jugendmedizin, Ulm. martin.wabitsch@uniklinik-ulm.de
Martin
M
Wabitsch
D003363:Cost Control / Q000639:trends; D003424:Crohn Disease / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016527:Drug Costs / Q000639:trends; D016568:Drugs, Generic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D004392:Dwarfism / Q000188:drug therapy*; D005544:Forecasting; D005858:Germany; D013006:Growth Hormone / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*
D016568:Drugs, Generic; D013006:Growth Hormone